OVID
Ovid Therapeutics Inc.
Biotechnology
Market Cap$355M
5Y Perf.-49.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OVID vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
OVID vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OVID | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $355M | $2.57B |
| Revenue (TTM) | $7M | $669M |
| Net Income (TTM) | $-17M | $-609M |
| Gross Margin | 99.2% | 83.6% |
| Operating Margin | -5.9% | -83.9% |
| Total Debt | $1M | $1.28B |
| Cash & Equiv. | $13M | $434M |
OVID vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OVID
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Ovid Therapeutics I… (OVID) | 100 | 51.0 | -49.0% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OVID vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OVID leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
OVID
Ovid Therapeutics Inc.
The Growth Play
OVID carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 11.8%, EPS growth 35.1%, 3Y rev CAGR 69.0%
- 11.8% revenue growth vs RARE's 20.1%
- +8.2% vs RARE's -21.8%
Best for: growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Income Pick
RARE is the clearest fit if your priority is income & stability and long-term compounding.
- Dividend streak 1 yrs, beta 1.42
- -59.4% 10Y total return vs OVID's -77.7%
- Lower volatility, beta 1.42, current ratio 2.48x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | OVID | 11.8% revenue growth vs RARE's 20.1% |
| Quality / Margins | RARE | -91.0% margin vs OVID's -240.1% |
| Stability / Safety | RARE | Beta 1.42 vs OVID's 1.45 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | OVID | +8.2% vs RARE's -21.8% |
| Efficiency (ROA) | OVID | -18.6% ROA vs RARE's -45.8%, ROIC -36.2% vs -89.4% |
OVID vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
OVID vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOVIDLAGGINGRARE
RAREUltragenyx Pharmaceut…
0leads
OVIDOvid Therapeutics Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OVID6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
OVID5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — OVID and RARE each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 92.3x OVID's $7M. Profitability is closely matched — net margins range from -91.0% (RARE) to -2.4% (OVID). On growth, OVID holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OVIDOvid Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $669M |
| EBITDAEarnings before interest/tax | -$42M | -$536M |
| Net IncomeAfter-tax profit | -$17M | -$609M |
| Free Cash FlowCash after capex | -$38M | -$487M |
| Gross MarginGross profit ÷ Revenue | +99.2% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -5.9% | -83.9% |
| Net MarginNet income ÷ Revenue | -2.4% | -91.0% |
| FCF MarginFCF ÷ Revenue | -5.3% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +8.4% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +192.3% | -17.2% |
Evenly matched — OVID and RARE each lead in 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — OVID and RARE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | OVIDOvid Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $355M | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $344M | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -11.38x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 49.01x | 3.82x |
| Price / BookPrice ÷ Book value/share | 1.54x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — OVID and RARE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
OVID leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
OVID delivers a -24.0% return on equity — every $100 of shareholder capital generates $-24 in annual profit, vs $-6 for RARE.
| Metric | OVIDOvid Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -24.0% | -6.1% |
| ROA (TTM)Return on assets | -18.6% | -45.8% |
| ROICReturn on invested capital | -36.2% | -89.4% |
| ROCEReturn on capital employed | -37.8% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | — |
| Net DebtTotal debt minus cash | -$12M | $842M |
| Cash & Equiv.Liquid assets | $13M | $434M |
| Total DebtShort + long-term debt | $1M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | — | -14.49x |
OVID leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
OVID leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OVID five years ago would be worth $7,845 today (with dividends reinvested), compared to $2,281 for RARE. Over the past 12 months, OVID leads with a +816.7% total return vs RARE's -21.8%. The 3-year compound annual growth rate (CAGR) favors OVID at -7.6% vs RARE's -17.8% — a key indicator of consistent wealth creation.
| Metric | OVIDOvid Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | +55.1% | +10.7% |
| 1-Year ReturnPast 12 months | +816.7% | -21.8% |
| 3-Year ReturnCumulative with dividends | -21.1% | -44.5% |
| 5-Year ReturnCumulative with dividends | -21.6% | -77.2% |
| 10-Year ReturnCumulative with dividends | -77.7% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -7.6% | -17.8% |
OVID leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — OVID and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
RARE is the less volatile stock with a 1.42 beta — it tends to amplify market swings less than OVID's 1.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OVID currently trades 87.9% from its 52-week high vs RARE's 61.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OVIDOvid Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.45x | 1.42x |
| 52-Week HighHighest price in past year | $3.10 | $42.37 |
| 52-Week LowLowest price in past year | $0.27 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +87.9% | +61.7% |
| RSI (14)Momentum oscillator 0–100 | 56.2 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 3.5M | 1.8M |
Evenly matched — OVID and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OVID as "Buy" and RARE as "Buy". Consensus price targets imply 97.1% upside for RARE (target: $52) vs 28.2% for OVID (target: $4).
| Metric | OVIDOvid Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $3.50 | $51.50 |
| # AnalystsCovering analysts | 14 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OVID leads in 2 of 6 categories — strongest in Profitability & Efficiency and Total Returns. 3 categories are tied.
Best OverallOvid Therapeutics Inc. (OVID)Leads 2 of 6 categories
Loading custom metrics...
OVID vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is OVID or RARE a better buy right now?
For growth investors, Ovid Therapeutics Inc.
(OVID) is the stronger pick with 1181% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Analysts rate Ovid Therapeutics Inc. (OVID) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OVID or RARE?
Over the past 5 years, Ovid Therapeutics Inc.
(OVID) delivered a total return of -21. 6%, compared to -77. 2% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: RARE returned -59. 4% versus OVID's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OVID or RARE?
By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.
(RARE) is the lower-risk stock at 1. 42β versus Ovid Therapeutics Inc. 's 1. 45β — meaning OVID is approximately 3% more volatile than RARE relative to the S&P 500.
04Which is growing faster — OVID or RARE?
By revenue growth (latest reported year), Ovid Therapeutics Inc.
(OVID) is pulling ahead at 1181% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Ovid Therapeutics Inc. grew EPS 35. 1% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, OVID leads at 69. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OVID or RARE?
Ultragenyx Pharmaceutical Inc.
(RARE) is the more profitable company, earning -85. 4% net margin versus -240. 1% for Ovid Therapeutics Inc. — meaning it keeps -85. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -79. 5% versus -585. 2% for OVID. At the gross margin level — before operating expenses — OVID leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OVID or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OVID or RARE better for a retirement portfolio?
For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (RARE: -59. 4%, OVID: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OVID and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(OVID: 844.7% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.